![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sanofi Indicted in France over Epilepsy Drug Depakine
Sanofi Indicted in France over Epilepsy Drug Depakine
February 11, 2020
Sanofi Aventis France was indicted as part of a criminal investigation relating to birth defects and slow neurological development linked to its epilepsy treatment Depakine (valproic acid).
The investigation began after a French inspection agency criticized the company’s response to the risks of taking the drug during pregnancy.
The FDA warned against the use of valproate anti-seizure products, including Depakine and its generics, in pregnant women in 2013 due to decreased IQ scores in exposed children.
Sanofi said that the indictment will allow the company to “demonstrate it has respected its duty to inform and show transparency.”
Upcoming Events
-
21Oct